Technologieangebote

The invention identifies new mutations in the TERT promoter which qualify as diagnostic and prognostic marker.

The invention describes a miRNA which interferes with glucocorticoid signalling and can therefore be used as a therapeutic target for e.g. diabesity-related metabolic disorders.

Side effects limit the radio/chemotherapeutic doses used during cancer treatment. Rocaglamide A and derivatives show strong chemo- and radioprotective efficacy, are highly specific for normal cells and do not protect p53-deficient/mutated cancer cells.

Non-ribosomal peptides (NRPs) are secondary metabolites produced by microorganisms, e.g. bacteria and fungi. Unlike ribosomal protein bio-synthesis, non-ribosomal protein synthesis (NRPS) does not require mRNA. NRPs are a promising source of functional molecules such as antibiotics. The technology allows for the identification, high-throughput screening and easy purification of engineered NRPs by optical measures.

The technology allows for direct and indirect detection of cancer tissue. It deals with a pharmaceutical compound consisting of three subdomains: (A) for specific cell surface binding to neoplastic cells, (B) for binding radiometals via a chelator domain for e.g. PET, and (C) harboring a fluorescent dye moiety for optical detection. The combination of PET tracer and optical moiety enables the surgeon to localize the tumor preoperatively via PET/CT and intraoperatively through optical detection.

The present invention discloses an antibody which selectively binds SITR1 dependent on its activation status.